Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRIDA: Fortelyzin vs Alteplase in Acute Ischemic Stroke
NCT03151993Phase 3Completed
- Sponsor
- SuperGen, Inc.
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of staphylokinase in ischemic stroke (2 arms), sponsored by SuperGen, Inc. Primary endpoint: Good Functional Recovery (mRS 0-1) at 90 days. Started Mar 2017; status: completed.
02
Drugs
staphylokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03151993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151993.